A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at
different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with
progressive supranuclear palsy. The patient study duration is 29 weeks including a washout
period.